Skip to main content
PMC home page
Gut logoLink to Gut
. 1998 Jun;42(6):792–794. doi: 10.1136/gut.42.6.792

Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours

S Angeletti 1, V Corleto 1, O Schillaci 1, M Marignani 1, B Annibale 1, A Moretti 1, G Silecchia 1, F Scopinaro 1, N Basso 1, C Bordi 1, F Delle 1
PMCID: PMC1727128  PMID: 9691916

Abstract

Background—Somatostatin receptor scintigraphy (SRS) and octreotide therapy have both changed the management of gastroenteropancreatic endocrine tumours, but very few data are available on the use of SRS and octreotide to visualise and treat somatostatinomas. 
Method—The results of SRS and octreotide treatment in three somatostatinoma patients were examined. 
Results—SRS was able to detect extensive hepatic involvement in patient 1, one hepatic and one pancreatic lesion in patient 2, and one hepatic lesion in patient 3. Octreotide therapy (0.5mg/day subcutaneously) was effective in decreasing plasma levels of somatostatin in all three patients. Symptoms (diabetes and diarrhoea) were greatly improved in the two patients with "somatostatinoma syndrome". 
Conclusion—The study shows that somatostatinoma, like most other gastroenteropancreatic endocrine tumours, possesses functioning somatostatin receptors. 



Keywords: somatostatin; octreotide; somatostatin receptor scintigraphy; gastroenteropancreatic endocrine tumour; somatostatinoma

Full Text

The Full Text of this article is available as a PDF (97.2 KB).

Figure 1 .

Figure 1

Open in a new tab

Histological appearance of duodenal somatostatinoma of patient 3 showing numerous gland-like structures often with psammoma bodies in the lumen (arrows) (haematoxylin and eosin stain; original magnification × 265). 


Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold R., Trautmann M. E., Creutzfeldt W., Benning R., Benning M., Neuhaus C., Jürgensen R., Stein K., Schäfer H., Bruns C. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996 Mar;38(3):430–438. doi: 10.1136/gut.38.3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bakker W. H., Albert R., Bruns C., Breeman W. A., Hofland L. J., Marbach P., Pless J., Pralet D., Stolz B., Koper J. W. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 1991;49(22):1583–1591. doi: 10.1016/0024-3205(91)90052-d. [DOI] [PubMed] [Google Scholar]
  3. Corleto V. D., Scopinaro F., Angeletti S., Materia A., Basso N., Polettini E., Annibale B., Schillaci O., D'Ambra G., Marignani M. Somatostatin receptor localization of pancreatic endocrine tumors. World J Surg. 1996 Feb;20(2):241–244. doi: 10.1007/s002689900038. [DOI] [PubMed] [Google Scholar]
  4. Corleto V. D., Severi C., Coy D. H., Delle Fave G., Jensen R. T. Colonic smooth muscle cells possess a different subtype of somatostatin receptor from gastric smooth muscle cells. Am J Physiol. 1997 Apr;272(4 Pt 1):G689–G697. doi: 10.1152/ajpgi.1997.272.4.G689. [DOI] [PubMed] [Google Scholar]
  5. Davis T. M., Bray G., Domin J., Bloom S. R. A case of somatostatinoma: responses to food and SMS 201-995 administration. Pancreas. 1988;3(6):729–733. [PubMed] [Google Scholar]
  6. John M., Meyerhof W., Richter D., Waser B., Schaer J. C., Scherübl H., Boese-Landgraf J., Neuhaus P., Ziske C., Mölling K. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut. 1996 Jan;38(1):33–39. doi: 10.1136/gut.38.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Konomi K., Chijiiwa K., Katsuta T., Yamaguchi K. Pancreatic somatostatinoma: a case report and review of the literature. J Surg Oncol. 1990 Apr;43(4):259–265. doi: 10.1002/jso.2930430414. [DOI] [PubMed] [Google Scholar]
  8. Kubota A., Yamada Y., Kagimoto S., Shimatsu A., Imamura M., Tsuda K., Imura H., Seino S., Seino Y. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest. 1994 Mar;93(3):1321–1325. doi: 10.1172/JCI117090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pipeleers D., Couturier E., Gepts W., Reynders J., Somers G. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab. 1983 Jun;56(6):1236–1242. doi: 10.1210/jcem-56-6-1236. [DOI] [PubMed] [Google Scholar]
  10. Reubi J. C., Lamberts S. W., Maurer R. Somatostatin receptors in normal and tumoral tissue. Horm Res. 1988;29(2-3):65–69. doi: 10.1159/000180970. [DOI] [PubMed] [Google Scholar]
  11. Reubi J. C. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1995 Oct;36(10):1825–1835. [PubMed] [Google Scholar]
  12. Reubi J. C., Waser B., Lamberts S. W., Mengod G. Somatostatin (SRIH) messenger ribonucleic acid expression in human neuroendocrine and brain tumors using in situ hybridization histochemistry: comparison with SRIH receptor content. J Clin Endocrinol Metab. 1993 Mar;76(3):642–647. doi: 10.1210/jcem.76.3.8095268. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES